Attenuation of D-galactose induced cardiac dysfunction through regulating glycation, NF-Κb, Nrf-2 expression: A phytotherapeutic approach

DOI

10.2991/978-94-6239-756-9_5How to use a DOI?

Keywords

D-Galactose; Glycation; Cardio-protection; Phytocomplex

Abstract

Aged heart is well-defined via functional and structural dysfunction. Presence of excessive D-gal activates glycation pathway, where excessive D-gal converts via non-enzymatic reaction with free amino groups to form advanced glycation end-products (AGEs). Further, AGEs and Receptor of AGEs (RAGE) interaction trigger oxidative stress and inflammation through regulating Nrf-2 and NF-κB pathway respectively. Current study aimed to evaluate the protective effect of the novel phytocomplex in D-gal-induced cardiac aging. Eight-week-old male albino Wistar rats have received D-gal (500 mg/kg body weight) subcutaneous injection for eight weeks. Afterwards, rats were treated intragastrically with three different doses of phytocomplex (high - 200 mg/kg body weight, medium - 100 mg/kg body weight, low - 50 mg/kg body weight) and rapamycin (1 mg/kg body weight) as a standard drug for four weeks. Tissue damage and Nrf2, NF-κB expressions were observed through histopathological and immunohistochemical analysis respectively. Cardiac tissue lysates were analyzed for glycation, oxidative stress, and detoxification markers. Phytocomplex treated groups have shown antiglycation properties through maintaining free amino and thiol group, suppressing β-amyloid aggregation and AGEs levels. Additionally, increased glutathione levels and catalase activity, reduced nitric oxide, malondialdehyde levels, advanced oxidation protein products formation, and aldose reductase activity in the phytocomplex treated groups collectively confirm its antioxidant activity. In histopathological study, phytocomplex treated groups have mitigated the D-gal-induced cardiac structural deterioration. Medium dose (100 mg/kg body weight) of phytocomplex has shown better antiglycation and antioxidant activity compared to other two doses.

Copyright

© 2026 The Author(s)

Open Access

Open Access This chapter is licensed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

Download article (PDF)

TY  - CONF
AU  - Subhrajeet Sahoor
AU  - Nilima Bangar
AU  - A. Anand Ganapathy
AU  - Alaganandam Kumaran
AU  - Rashmi S. Tupe
PY  - 2026
DA  - 2026/08/31
TI  - Attenuation of D-galactose induced cardiac dysfunction through regulating glycation, NF-Κb, Nrf-2 expression: A phytotherapeutic approach
BT  - Proceedings of the Conference on Bioengineering for Global Health (SYMRESEARCH 2.0 2025)
PB  - Atlantis Press
SP  - 45
EP  - 61
SN  - 2468-5747
UR  - https://doi.org/10.2991/978-94-6239-756-9_5
DO  - 10.2991/978-94-6239-756-9_5
ID  - Sahoor2026
ER  -